Review and update of the American Psychiatric Association Practice Guideline for Bipolar Disorder

Primary Psychiatry

Volumn 11, Issue 9, 2004, Pages 73-84

  Chou, James C Y ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; FLUPENTIXOL DECANOATE; GABAPENTIN; HALOPERIDOL; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; ZIPRASIDONE;

ACNE; ALOPECIA; BEHAVIOR THERAPY; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DIABETES INSIPIDUS; DRUG CHOICE; DRUG DEPENDENCE; EDEMA; ELECTROCONVULSIVE THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; LONG TERM CARE; MANIA; MEDICAL SOCIETY; MONOTHERAPY; NEPHROTOXICITY; OVARY POLYCYSTIC DISEASE; PANCREATITIS; POLYPHARMACY; PRACTICE GUIDELINE; PROPHYLAXIS; PSYCHODYNAMICS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKILL; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; TREMOR; WEIGHT GAIN;

EID: 4944238823     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(suppl 4):1-50.
2. Bowden CL, Brugger AM, Swann AC, et al, for the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918-924. Erratum in: JAMA. 1994;271(23):1830.
3. Bowden CL, Brugger AM, Swann AC, et al, for the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918-924. Erratum in: JAMA. 1994;271(23):1830.
4. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60(2):79-88.
5. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912.
6. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression, J Clin Psychiatry. 1994;55(9):391-393.
7. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164(4):549-550.
8. Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol. 1991;11(1):3-21.
9. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic depressive illness. A comparison with lithium. Acta Psychiatr Scand. 1981;64(3):226-237.
10. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry. 1986;148:723-725.
11. Chouinard G, Young SN, Annable L. Antimanic effects of clonazepam. Biol Psychiatry. 1983;18(4):451-466.
12. Chouinard G. The use of benzodiazepines in the treatment of manic-depressive illness. J Clin Psychiatry. 1988;49(suppl):15-20.
13. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J Clin Psychiatry. 1987;48(suppl):29-37.
14. Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol. 1990;10(6):403-408.
15. Modell JG, Lenox RH, Weiner S. Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol. 1985;5(2):109-113.
16. Lenox RH, Modell JG, Weiner S. Acute treatment of manic agitation with lorazepam. Psychosomatics. 1986;27(suppl 1):28-32.
17. Kane JM, Woerner M, Weinhold P. Incidence and severity of tardive dyskinesia in affective illness. In: Gardos G, Casey DE, eds. Tardive Dyskinesia and Affective Disorders. Washington, DC: American Psychiatric Press; 1984:21-28.
18. Tohen M, Sanger TM, McElroy SL, et al, for the Olanzapine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702-709.
19. Tohen M, Jacobs TG, Grundy SL, et al, for the Olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57(9):841-849.
20. Tohen M, Bowden C, Calabrese J, et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial. Bipolar Disord. 2004;6(4):26-27.
21. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. Erratum in: Arch Gen Psychiatry. 2004;61(2):176.
22. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. Erratum in: Arch Gen Psychiatry. 2004;61(2):176.
23. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146-1154.
24. Jody D, Marcus R, Keck P, et al. Aripiprazole vs. placebo in acute mania. Int J Neuropsychopharmacol. 2002;5(suppl 1):S57.
25. Mullen J, Devine N, Sweitzer D. Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM). Poster presented at: American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco, CA.
26. Bourin M, Auby P, Marcus RN, et al. Aripiprazole versus haloperidol for maintained treatment effect in acute mania. Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
27. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K, for the Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741-748.
28. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146-1154.
29. Inoue K, Arima S, Tanaka K, Fukui Y, Kato N. A lithium and carbamazepine combination in the treatment of bipolar disorder-a preliminary report. Folia Psychiatr Neurol Jpn. 1981;35(4):465-475.
30. Nolen WA. Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. Acta Psychiatr Scand. 1983;67(4):218-225.
31. Lipinski JF, Pope HG Jr. Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients. Am J Psychiatry. 1982;139(7):948-949.
32. Kramlinger KG, Post RM. Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand. 1989;79(4):378-385.
33. Desai NG, Gangadhar BN, Channabasavanna SM, Shetty KT. Carbamazepine hastens therapeutic action of lithium in mania. Paper presented at: International Conference on New Directions in Affective Disorders; April 5-9, 1987; Jerusalem, Israel.
34. Keck PE Jr, McElroy SL, Vuckovic A, Friedman LM. Combined valproate and carbamazepine treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci. 1992;3:319-322.
35. Solomon DA, Ryan CE, Keitner GI, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry. 1997;58(3):95-99.
36. Chou JC, Czobor P, Charles O, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol. 1999;19(6):500-505.
37. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder. Arch Gen Psychiatry. 1979;36(3):327-333.
38. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry. 1984;41(11):1096-1104.
39. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord. 1980;2(4):279-288.
40. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J, for the European Valproate Mania Study Group. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol. 2000;20(2):195-203.
41. Emrich HM. Experience with oxcarbazepine in acute mania. In: Modigh K, Robak OH, Vestergaard P, eds. Anticonvulsants in Psychiatry. Petersfield, UK: Wrightson Biomedical Publishing; 1994:29-36.
42. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993;13(6):397-408.
43. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
44. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152(8):1130-1138.
45. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145(2):179-184.
46. Crane GE. The psychiatric side-effects of iproniazid. Am J Psychiatry. 1956;112(7):494-501.
47. Arnold OH, Kryspin-Exner K. The problem of control of manic-depressive processes by antidepressants [in German]. Wien Med Wochenschr. 1965;115(45):929-934.
48. Till E, Vukovic AJ. Int Pharmacopsychiatry. 1970;5:13-17.
49. Coppen A, Brooksbank BW, Peet M. Tryptophan concentration in the cerebrospinal fluid of depressive patients. Lancet. 1972;1(7765):1393.
50. van Scheyen JD, van Kammen DR Clonripramine-induced mania in unipolar depression. Arch Gen Psychiatry. 1979;36(5):560-565.
51. Siris SG, Chertoff HR, Perel JM. Rapid-cycling affective disorders during imipramine treatment: a case report. Am J Psychiatry. 1979;136(3):341-342.
52. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980;13(4):156-167.
53. Lerer B, Birmacher B, Ebstein RP, Belmaker RH. 48-hour depressive cycling induced by antidepressant. Br J Psychiatry. 1980;137:183-185.
54. Ko GN, Leckman JF, Heninger GR. Induction of rapid mood cycling during L-dopa treatment in a bipolar patient. Am J Psychiatry. 198;138(12):1624-1625.
55. Mattsson A, Seltzer RL. MAOI-induced rapid cycling bipolar affective disorder in an adolescent. Am J Psychiatry. 1981;138(5):677-679.
56. Extein I, Pottash AL, Gold MS. Does subclinical hypothyroidism predispose to tricyclic-induced rapid mood cycles? J Clin Psychiatry. 1982;43(7):290-291.
57. Oppenheim G. Drug-induced rapid cycling: possible outcomes and management. Am J Psychiatry. 1982;139(7):939-941.
58. Ghaemi SN, Boiman EE, Goodwin FK: Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry. 2000;61(10):804-808.
59. Calabrese JR, Suppes T, Bowden CL, et al, for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61(11):841-850.
60. Bowden CL, Calabrese JR, Sachs G, et al, for the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
61. Goodwin FK, Bowden CL, Calabrese JR, et al. Maintenance treatments for bipolar I depression (lithium, lamotrigine, and placebo). Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
62. Bowden CL, Calabrese JR, McElroy SL, et al, for the Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57(5):481-489.
63. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v, mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.